More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

BioArctic’s partner Eisai presented real-world Lecanemab data from the LEADER Study in early Alzheimer’s disease, reporting that nearly 83% of enrolled patients had early AD. The news is supportive of real-world performance and adoption of the therapy, though specific clinical efficacy/endpoint results were not included in the excerpt. Overall, this should modestly improve sentiment toward BioArctic/Eisai’s Alzheimer’s program.

Analysis

BioArctic’s partner Eisai presented real-world Lecanemab data from the LEADER Study in early Alzheimer’s disease, reporting that nearly 83% of enrolled patients had early AD. The news is supportive of real-world performance and adoption of the therapy, though specific clinical efficacy/endpoint results were not included in the excerpt. Overall, this should modestly improve sentiment toward BioArctic/Eisai’s Alzheimer’s program.